Genfit SA

( )
GNFT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.17%60.590.0%$1954.52m
REGNRegeneron Pharmaceuticals, Inc. -0.95%598.542.5%$1194.19m
GILDGilead Sciences, Inc. 4.22%77.541.0%$991.43m
AMGNAmgen, Inc. -0.05%220.881.3%$628.89m
NVAXNovavax, Inc. 0.93%44.66102.0%$620.64m
VRTXVertex Pharmaceuticals, Inc. -1.51%272.821.9%$540.62m
ILMNIllumina, Inc. 0.02%358.403.5%$384.32m
BIIBBiogen, Inc. -0.98%299.651.6%$368.00m
ALXNAlexion Pharmaceuticals, Inc. -0.08%113.682.0%$250.86m
SRNESorrento Therapeutics, Inc. -6.76%3.861.8%$246.90m
SGENSeattle Genetics, Inc. -2.98%150.436.1%$229.28m
AAgilent Technologies, Inc. 0.70%91.121.6%$215.04m
BMRNBioMarin Pharmaceutical, Inc. -3.33%107.514.3%$187.14m
MGNXMacroGenics, Inc. -2.52%20.486.2%$164.68m
INCYIncyte Corp. -5.09%93.802.5%$153.77m

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.